The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
Open accessAbstract
OBJECTIVE: To determine whether chronic atrial fibrillation is associated with abnormalities in plasma fibrinogen, von Willebrand factor (vWF) (a marker of endothelial disturbance), or fibrin D- dimer (a measure of fibrin turnover); and if so, whether such levels are related to haemodynamic disturbance (enlarged left atrium, poor left ventricular function) or existing treatment with warfarin or aspirin. To investigate the effects of introducing warfarin in patients with atrial fibrillation on fibrinogen and D- dimer levels. DESIGN: Cross sectional population sample controlled study and longitudinal study of patients undergoing anticoagulation. SETTING: District general hospital. SUBJECTS: 87 patients (44 men and 43 women of mean (SEM) age 63.0 (1.0)) with chronic atrial fibrillation. At the time of the study, 37 were taking no antithrombotic medication (group 1), 31 were taking warfarin (including two on warfarin and aspirin) (group 2) and 19 were taking aspirin alone (group 3). They were compared with 158 population controls from a random population sample (the second Glasgow monitoring trends and determinants in cardiovascular disease study). As part of clinical treatment warfarin was introduced in 20 patients with chronic atrial fibrillation (14 men and six women of mean (SEM) (range) age 63.9 (2.35 (32-74) years). RESULTS: Plasma fibrinogen remained significantly increased in patients of group 1 (no antithrombotic medication) compared with that of the population controls (median difference 1.23 g/l; 95% confidence interval (CI) 0.88 to 1.62, P < 0.0001). There was also a significant increase in plasma D-dimer levels (median difference 77 ng/ml; 95% CI 38 to 122, P < 0.01) and vWF (median difference 63 IU/dl; 95% CI 38 to 89, P < 0.0001). There was no significant difference in plasma fibrinogen (median difference 0.14 g/l; 95% CI -0.44 to 0.77, P = 0.65) or vWF (median difference 3.5 IU/dl; 95% CI - 41 to 41, P = not significant in patients of group 2 (warfarin treatment) compared with that of patients in group 1. Levels of D-dimer were significantly lower in group 2 (median difference 90 ng/ml, 95% CI 39 to 150, P < 0.0001) than in group 1. There were no significant differences in plasma fibrinogen (median difference 0.08 g/l; 95% CI - 0.52 to 0.77, P = 0.73), D-dimer (median difference - 34 ng/ml; 95% CI - 114 to 21.0, P = 0.25), or vWF (median difference 2%; 95% CI - 35 to 41, P = not significant) levels between patients of groups 1 and 3. There were no significant correlations between the coagulation indices and left atrial volume or ventricular function. There was a significant positive correlation between plasma fibrin D-dimer and vWF levels in patients of groups 1 and 3 (r = 0.52, P < 0.001). There was a significant reduction in median plasma fibrin D-dimer levels at 2 months after the introduction of warfarin (181 ng/ml v 80 ng/ml, P < 0.001), but no effect on plasma fibrinogen. CONCLUSIONS: Increased median plasma fibrinogen and vWF levels were found in patients with chronic atrial fibrillation. Plasma D-dimer levels were also increased in patients with chronic atrial fibrillation not receiving warfarin, suggesting increased intravascular thrombogenesis in such patients. Introduction of warfarin normalised circulating fibrin D- dimer levels, suggesting that warfarin treatment was effective in preventing excessive fibrin turnover, consistent with the antithrombotic effects of warfarin. These results suggest three possible thrombotic markers to assess patients with atrial fibrillation who are at high risk of thrombogenesis; D-dimer also merits assessment as a measure of reduction in thrombotic risk in patients receiving warfarin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sahn, D. J., DeMaria, A., Kisslo, J., & Weyman, A. (1978) · Circulation · doi:10.1161/01.cir.58.6.1072 · Cited by 7,430
Fibrinogen as a Risk Factor for Stroke and Myocardial Infarction
Wilhelmsen, L., Svärdsudd, K., Korsan-Bengtsen, K., Larsson, B., Welin, L., & Tibblin, G. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408233110804 · Cited by 1,646
Fibrinogen as a Cardiovascular Risk Factor: A Meta-Analysis and Review of the Literature
Ernst, E., & Resch, K. L. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-12-199306150-00008 · Cited by 990
Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study.
Sanfilippo, A. J., Abascal, V. M., Sheehan, M., Oertel, L. B., Harrigan, P., Hughes, R. A., & Weyman, A. E. (1990) · Circulation · doi:10.1161/01.cir.82.3.792 · Cited by 739
HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY
Meade, T. W., Chakrabarti, R., Haines, A. P., North, W. R. S., Stirling, Y., Thompson, S. G., & Brozović, M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91498-1 · Cited by 690
von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.
Jansson, J. H., Nilsson, T. K., & Johnson, O. (1991) · Heart · doi:10.1136/hrt.66.5.351 · Cited by 357
Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation.
Gustafsson, C., Blombäck, M., Britton, M., Hamsten, A., & Svensson, J. (1990) · Stroke · doi:10.1161/01.str.21.1.47 · Cited by 308
Fowkes, F. G. R., Housley, E., Rattray, A., Lowe, G. D. O., Rumley, A., Elton, R. A., MacGregor, I. R., & Dawes, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91288-w · Cited by 192
Self-citationIncreased intracardiovascular clotting in patients with chronic atrial fibrillation
Kumagai, K., Fukunami, M., Ohmori, M., Kitabatake, A., Kamada, T., & Hoki, N. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)90589-h · Cited by 184
Ritchie, D. G., Levy, B., Adams, M. A., & Fuller, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.5.1530 · Cited by 118
Cited by
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,123
Self-citationGoette, A., Kalman, J. M., Aguinaga, L., Akar, J., Cabrera, J. A., Chen, S. A., Chugh, S. S., Corradi, D., D’Avila, A., Dobrev, D., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2016.05.028 · Cited by 771
Self-citationGoette, A., Kalman, J. M., Aguinaga, L., Akar, J., Cabrera, J. A., Chen, S. A., Chugh, S. S., Corradi, D., D'Avila, A., Dobrev, D., et al. (2016) · Europace · doi:10.1093/europace/euw161 · Cited by 762
Self-citationvon Willebrand factor: a marker of endothelial dysfunction in vascular disorders?
Lip, G. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00039-4 · Cited by 455
Self-citation
Metadata
- Authors
- Lip, G. Y., Lowe, G. D., Rumley, A., & Dunn, F. G.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 1995-06-01
- Volume
- 73
- Issue
- 6
- Pages
- 527-533
- ISSN
- 1355-6037 (ISSN-L)
- OpenAlex
- W2143159730
- Cited by
- 296
- References
- 14
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. https://app.cochat.ai/papers/10.1136/hrt.73.6.527
- The paper
- Lip, G. Y., Lowe, G. D., Rumley, A., & Dunn, F. G. (1995). Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Heart. https://doi.org/10.1136/hrt.73.6.527
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.